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The Multidisciplinary Management of Type 2 and Gestational Diabetes in Pregnancy 
Abstract 
The UK is experiencing a dramatic increase in prevalence of type 2 diabetes mellitus (T2D). 
Consequently there is a corresponding increase in diabetes in pregnancy, with 87.5% of the 
pregnancies complicated by diabetes due to GDM and 27% of those with pre-existing 
diabetes having T2D. Although the risks to mother and baby are similar to type 1diabetes 
(T1D), the approach and management often differ. Women with GDM and T2D are more 
likely to be older, multiparous and live in deprived areas. Certain ethic groups are more 
prone to GDM and T2D and there is a strong association with being overweight and obesity. 
Women who develop GDM in pregnancy have an increased risk of T2D in later life. Some 
surveys have shown that women with T2D often receive suboptimum care prior to 
conception and in early pregnancy. This paper presents an overview of the multidisciplinary 
management of T2D and GDM in pregnancy and identifies areas where care may be lacking 
for these women. 
Introduction 
Diabetes is the most common medical disorder affecting pregnancy in the UK with 
approximately 2 - 5% of pregnant women having diabetes (NICE 2008a). The majority of 
pregnancies complicated by diabetes are due to gestational diabetes (GDM) (87.5%). GDM 
develops during the latter half of pregnancy and is caused by increased insulin resistance; 
some women unknowingly have chronic insulin resistance prior to pregnancy, which is then 
exacerbated by the physiological changes of pregnancy (Metzger et al 2007). Increased 
production of female hormones in all pregnancies leads to increased insulin resistance, 
resulting in increased demands for insulin. In those women where pancreatic insulin 
production is unable to meet demand, transient diabetes develops (Buchanan et al, 1990; 
Butte, 2000). Although β-cell production of insulin increases in all pregnancies, those with 
GDM have lower insulin secretion for their degree of insulin resistance, compared to women 
with normal glucose tolerance (Metzger et al 2007). 
 
The UK is experiencing a dramatic increase in the prevalence of GDM and type 2 diabetes 
(T2D) in pregnancy as factors other than pregnancy can also increase insulin resistance, 
predominantly increasing age and increased adipose tissue (Diabetes UK, 2011a). The 
increasing prevalence of overweight and obesity in pregnancy is largely to blame. The UK is 
experiencing an increase in T2D in younger people in general, with 1.5% of children with 
diabetes now reported to have T2D. Prior to 2002, T2D was unknown in children (Diabetes 
UK 2012b). The Confidential Enquiry into Maternal and Child Health (CEMACH 2007) found 
that 27% of pregnant women with pre-existing diabetes had T2D. Furthermore, women with 
T2D were also more likely to be older, multiparous and live in deprived areas. Pregnant 
women with T2D were more likely to be obese (BMI >30 kg/m2), with 62% of those with T2D 
and 15% with type 1 diabetes (T1D) being classed as obese (P<0.001) (CEMACH, 2005). 
Certain ethnic groups are also more likely to develop GDM or T2D particularly people of 
African, black Caribbean, South Asian, Middle Eastern and Chinese family origin (NICE 
2008a). Women who are diagnosed with GDM have a 30% risk of developing T2D during 
their lifetime, compared with a 10% risk in the general population (Diabetes UK, 2011a). 
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Diabetes in pregnancy is classed as a high risk pregnancy as it is associated with a number 
of complications for both mother and baby (Table 1). 
 
Table 1. Complications of pregnancy associated with different types of diabetes 
Complication Type of DM 
Maternal Ketoacidosis and hypoglycaemia Type 2 
Miscarriage Type 2 
Genetic malformation Type 2 
Still birth/ Fetal death Type 2, GDM 
Polyhydramnios Type 2, GDM 
Pre-eclampsia Type 2 
Macrosomia/Large for gestational age Type 2, GDM 
Shoulder dystocia/ Birth trauma Type 2, GDM 
Neonatal hypoglycaemia Type 2, GDM 
Induction of labour or caesarean section Type 2, GDM 
Transient neonatal morbidity  Type 2, GDM 
Obesity and/or diabetes developing later in the baby’s life Type 2, GDM 
(Diabetes UK, 2002; NICE, 2008a). 
Table one shows that T2D incurs similar risks as T1D, despite T2D often being viewed as a 
less serious condition. Women with T2D are more at risk of hypertension during pregnancy 
(Diabetes UK 2008a). GDM is associated more with complications occurring at the end of 
pregnancy and during the birth of the baby. CEMACH (2007) found that pregnancy 
outcomes were equally poor in women with T2D as those with T1D and poor glycaemic 
control based on HbA1c results in early pregnancy was the most significant risk factor for 
both congenital malformations and stillbirth. Early diagnosis and access to appropriate 
multidisciplinary specialist maternity care are essential in achieving good glycaemic control 
and so limiting risk of complications (Diabetes UK, 2011b). 
 
GDM Diagnosis 
NICE (2008a) recommend screening all women to identify those at high risk (table 2). Once 
identified these women should be tested for GDM using a 2-hour 75 g oral glucose tolerance 
test (OGTT). Diagnosis is made using the criteria defined by the World Health Organization 
(WHO) which is a fasting blood glucose > 7 mmol/l and/or a 2 hour blood glucose > 7.8 
mmol/l. OGTT should be offered at 24-28 weeks gestation; women with previous GDM 
should be screened earlier at 16-18 weeks (and again at 28 weeks if first OGTT is normal) 
(NICE, 2008a). 
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Table 2: Women at increased risk of GDM who require screening with OGTT 
Body mass index (BMI) > 30 kg/m2  
Previous macrosomic baby weighing 4.5 kg or above  
Previous gestational diabetes  
Family history of diabetes (first-degree relative with diabetes)  
Family origin with a high prevalence of diabetes:  
South Asian (specifically women whose country of family origin is India, 
Pakistan or Bangladesh)  
Black Caribbean  
Middle Eastern (specifically women whose country of family origin is Saudi 
Arabia, United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, 
Lebanon or Egypt).  
(NICE, 2008a) 
There is some debate about the use of WHO criteria to diagnose GDM as glucose tolerance 
changes with duration of pregnancy (Diabetes UK 2011c). Furthermore, different criteria are 
used in the USA where all pregnant women are screened and the diagnosis of GDM is made 
when any of the following plasma glucose values are exceeded:  
 Fasting ≥ 5.1 mmol/l 
 1 h ≥ 10.0 mmol/l 
 2 h ≥ 8.5 mmol/l  (American Diabetes Association 2012) 
Should these criteria be adopted in the UK, the prevalence of women diagnosed with GDM 
would increase significantly, further increasing the demand for finite specialist resources. 
However, American clinicians argue that previous criteria would not identify some women at 
risk of poor pregnancy outcome, as outlined in the Hyperglycaemia and Adverse Pregnancy 
Outcomes (HAPO) study (Metzger et al., 2008). 
Type 2 Diabetes and Pre-conceptional care 
Women with pre-existing T2D require advice and support from the Multidisciplinary Team 
(MDT) regarding planning pregnancy as good glycaemic control at the time of conception 
and in early pregnancy can reduce the risk of many pregnancy complications (NICE 2008a). 
Despite this, only about one third of women with T2D access pre-conceptional care 
(CEMACH 2007).  
Women should be advised to access pre-conceptual care with their Diabetes Specialist 
Nurse to achieve an HbA1c of 6.1% or lower before conception (NICE 2008a) and to aim for 
the following: 
 Blood glucose < 5.6 mmol/l before meals or < 7.8 mmol/l 2 hours after eating. 
 Avoid smoking and alcohol. 
 Eat a healthy balanced diet. 
 Folic acid supplementation of 5 mg/day (higher than the recommended dose 
for the general population). This should be taken prior to conception and up to 
12 weeks gestation. 
 Have retinal screening to check for signs of retinopathy 
 Check blood pressure. 
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 Check medication as some medications commonly used in T2D are 
contraindicated in pregnancy, e.g. statins, angiotensin-converting enzyme 
(ACE) inhibitors or angiotensin-11 receptor antagonists. Also oral 
hypoglycaemic agents (OHA) other than Metformin e.g. Glibenclamide, need 
to be replaced with either Metformin or insulin. 
(Diabetes UK 2006; Diabetes UK 2011d; NICE 2008a). 
Women should also have a review by the specialist midwife within the MDT where positive 
pregnancy information can be given; the rubella status can be reviewed; advice about 
stopping alcohol consumption, starting folic acid and help to stop smoking can be made. 
Moreover, a realistic plan can then be made about when to advice women to stop using 
contraception. 
Role of the Multidisciplinary Team 
 
CEMACH (2007) found preconception care lacking for many pregnant women with diabetes, 
particularly those with T2D (25% T2D compared to 38% T1D). Less than a fifth (17%) of 
maternity clinics offered a structured, maternity multidisciplinary service. According to 
medical records less than half of women were taking folic acid supplements, with only a 
minority taking the correct dose of one 5 mg tablet per day. Folic acid supplementation was 
lower for women with T2D (29% compared to 43% T1D). Less than half of women had been 
advised about glycaemic control, diet, contraception, complications and alcohol prior to 
pregnancy. Two thirds of women (79%) had suboptimal glycaemic control prior to conception, 
despite this only a minority were documented to be using contraception and only 54% had 
HbA1C recorded in the 12 months prior to pregnancy. 
 
As a result a number of recommendations were made aiming to improve preconception care, 
in particular, ensuring that all women with diabetes have access to all members of the 
specialist multidisciplinary team (MDT). As a minimum this should include an obstetrician; a 
diabetes physician; a diabetes specialist nurse; diabetes specialist midwife and a dietitian. 
(CEMACH, 2007; DOH, 2001). In 2012 Diabetes UK published a list of ‘15 Essentials’ 
regarding diabetes care. One of these essentials (13) is access to specialist care when 
pregnant or planning pregnancy (Diabetes UK 2012a). 
It was also acknowledged that less than half of women with diabetes had a planned 
pregnancy with only 27% reported to be using contraception prior to pregnancy (CEMACH 
2007). Therefore, preconception care and adequate contraceptive provision should be a key 
aspect of general diabetes care, both in primary and secondary care, for all women of child 
bearing age from adolescents onwards (DOH 2003). This is particularly true for women with 
T2D as many have their diabetes care within primary care settings.  
Antenatal care 
Pregnant women with T2D require immediate referral to all members of the specialist MDT 
as soon as pregnancy is confirmed (NICE 2008a). Ideally all members of the MDT will be in 
clinic at the same time and each speciality will be recognised and valued for their unique 
contribution to care during pregnancy. CEMACH (2007) found that only one fifth of women 
had all members of the MDT involved in their care. Women with diabetes require additional 
care over and above routine antenatal care (as outlined by NICE 2008b). In particular, 
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frequent contact with the MDT is essential to ensure relevant education and updated 
information is provided. NICE (2008a) recommends appointments every 1-2 weeks 
throughout pregnancy primarily to monitor and assess glycaemic control if there are no 
significant complications of diabetes present. If there are significant complications an 
individualised plan of care should be made with women being seen weekly or more often if 
necessary. 
NICE (2008a) provides very detailed information regarding specific antenatal care for 
diabetes, highlighting assessments and information that should be provided at each 
appointment. To summarise, women with T2D and GDM will require individualised advice 
regarding blood glucose targets and monitoring. Moreover, additional education regarding 
insulin management is needed, as many will be commencing insulin for the first time and 
insulin doses change throughout pregnancy (Rayburn et al 1985). Women taking insulin will 
require detailed advice regarding preventing and managing hypoglycaemia, particularly if 
newly commencing insulin, plus detecting and managing ketoacidosis. Both conditions can 
be more prevalent in diabetic pregnancy and can occur with less warning because of 
metabolic changes in pregnancy (Rayburn et al 1986). 
The importance of medical / obstetric assessment during antenatal care for women with T2D 
should entail the detection and monitoring of diabetic complications such as retinopathy, 
nephropathy and neuropathy (NICE 2008a). Underlying complications often worsen during 
pregnancy, particularly if undetected or with poor glycaemic control (Diabetes UK 2011d). 
These women should be offered a retinal and renal assessment as soon as possible by the 
diabetes physician at the MDT antenatal clinic, particularly if this has not been performed in 
the last 12 months. NICE (2008a) detail continuous monitoring of these conditions and 
indicate when women may need referral for specialist care to manage them.  
CEMACH (2007b) found that women aged over 35 years and those with pre-existing medical 
conditions including hypertension and T2D had greater risk of cardiovascular disease; 
monitoring with electrocardiograph (ECG) is recommended in these cases. Furthermore, as 
women with T2D have increased risk of hypertensive disorders in pregnancy and low dose 
aspirin is known to protect individuals with diabetes against hypertension (Diabetes UK 
2009), one 75mg tablet of aspirin is recommended daily from 12 weeks gestation until the 
birth of the baby. 
Role of the midwife 
The midwife is a key member of the MDT as the keeper of ‘normality’ within a high risk 
pregnancy. This role is vital for woman with diabetes so that normal pregnancy information 
and planning does not get lost within a medical model of care. The diabetes midwives role is 
crucial in ensuring that women are looked after by a midwife with expert knowledge about 
diabetes so that problems can be identified and plans can be made within a combined 
medical and midwifery approach to care. An important aspect of this care is ensuring that 
women get consistent information from all members of the team based on best evidence.  
As poor pregnancy outcome is more prevalent with T2D, additional monitoring and screening 
of fetal development is essential. Ultrasound scans in early pregnancy for dating (preferably 
7 – 9 weeks), the combined test for Down’s screening (10 – 13 weeks) and for fetal anatomy 
(to include 4-chamber view and outflow tracts at approximately 20 weeks) are used to detect 
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fetal abnormalities such as heart defects or nuchal fold thickening (NICE, 2008a; Locatelli et 
al, 2000). Later ultrasound scans are used to monitor fetal growth, fetal wellbeing 
(uteroplacental and umbilical artery doppler) and amniotic fluid volume (NICE 2008a). 
CEMACH (2007a) found that nearly half of babies with macrosomia did not receive adequate 
fetal surveillance and this was associated with fetal and neonatal death. Due to increased 
risk of still birth, tests for fetal wellbeing in GDM and T2D, such as cardiotocographic (CTG) 
monitoring can be used after 28 weeks gestation when necessary (Polyhydramnios, 
accelerated growth or risk of IUGR) and all women need detailed advice regarding 
monitoring of fetal movements (RCOG 2011). 
Role of the dietitian  
Access to a specialist dietitian is essential to help women achieve the optimum healthy diet 
for diabetes in pregnancy, especially if new to diabetes (GDM) or new to insulin (T2D). 
Women will require education to identify sources of dietary carbohydrate, amount of 
carbohydrate and an awareness of glycaemic index. Some women with GDM manage their 
diabetes with low sugar diet alone when given appropriate dietary advice and guidance. 
Pregnant women also require advice regarding food hygiene and foods contraindicated in 
pregnancy as part of their routine antenatal care (see NHS 2011a; NHS 2011b for details). 
Specialist dietetic advice can also help if women have additional challenges such as 
overweight/obesity; hypoglycaemia; severe nausea/vomiting, or if they haven’t seen a 
dietitian before or for some time and their T2D dietary information is outdated. Despite this, 
CEMACH (2007a) found that less than half of pregnant women with diabetes had access to 
a dietitian. 
 
Care during labour and birth 
Women with pregnancies complicated by diabetes should be offered delivery in a consultant-
led unit, with neonatal intensive care available. Women should also have continuous 
electronic fetal monitoring throughout labour and a paediatrician should also be present at 
the birth as women have an increased risk of IUGR, macrosomia and instrumental delivery 
(Diabetes UK 2008). Where possible, the aim is for vaginal delivery but pregnancy problems 
such as fetal macrosomia or previous caesarean section may indicate a need to consider 
caesarean section (NICE 2008a). Rates of caesarean section tend to be higher in diabetic 
pregnancies (Diabetes UK 2008). 
Due to the risk of stillbirth, induction of labour or caesarean section is offered between 38 
and 39 weeks gestation if pregnancy is progressing with a healthy woman, good glycaemic 
control and a normally grown fetus (NICE 2008a). Babies who are likely to be delivered 
earlier than 37 weeks (due to complications such as pre-eclampsia, IUGR, fetal distress) are 
recommended to have a course of intramuscular corticosteroids (two doses 12 hours apart) 
for fetal lung maturation to prevent neonatal respiratory distress syndrome. Women with 
insulin treated T2 and GDM, receiving steroids should be admitted and receive additional 
insulin and blood glucose monitoring, to prevent maternal hyperglycaemia and possible 
ketoacidosis (NICE 2008a; Diabetes UK 2008). 
Throughout labour and delivery (and caesarean section), blood glucose should be monitored 
hourly aiming to maintain blood glucose levels between 4-7 mmol/l (NICE 2008a). All women 
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with T2D should have intravenous dextrose and insulin infusion during established labour, 
prior to and immediately after caesarean section. 
Some consideration may be needed regarding possible hypoglycaemia; that is some 
flexibility with women expected to be ‘Nil by mouth’ where oral dextrose tablets could be 
administered. Women who have required insulin during pregnancy intravenous insulin and 
dextrose should be considered (Diabetes UK 2008a). 
Postnatal care 
Once the baby and placenta are delivered there is a sudden reduction in insulin resistance 
which dramatically reduces the demand for maternal insulin (Abayomi et al 2005; Diabetes 
UK 2008a). The postnatal plan in general for these women should be as follows: 
 Women with T2D and GDM who were treated with insulin only during their pregnancy 
should stop insulin immediately after the birth of the baby.  
 Women who were treated with oral hypoglycaemic agents (OHA) before pregnancy 
should resume their pre-pregnancy dose, however only Metformin and Glibenclamide 
are recommended during breastfeeding. Other OHA and other medication 
discontinued during pregnancy should be avoided whilst breastfeeding (NICE 2008a).  
 Women who managed GDM or T2D with diet prior to pregnancy but were treated 
with OHA (Metformin tablets) and diet during pregnancy, should stop Metformin 
immediately after delivery (Diabetes UK 2008a).  
 Those with GDM can also cease blood monitoring.  
 All women should be managed as high risk for thromboembolism because of the 
increased risks of deep venous thrombosis particularly due to obesity, increased age, 
instrumental delivery or caesarean section (Simpson et al 2001) 
The midwives role in minimising postpartum separation of mother and baby is crucial in 
supporting successful breastfeeding (Haninger and Farley 2001). All midwives should aim to 
keep babies with their mothers unless there is a clear medical indication for admission to 
neonatal intensive care unit (NICU). Previously, babies born to women with diabetes were 
routinely admitted to NICU but this should no longer be the case. Despite this, CEMACH 
(2007a) found that one third of NICU admissions occurred due to routine diabetes policy.  
 
If women were treated with insulin in pregnancy and particularly if glycaemic control was 
poor there is a recognised risk of neonatal hypoglycaemia (blood glucose <2.0 mmol/l) 
(Diabetes UK 2008a). To prevent this, women should be encouraged to feed their baby as 
soon as possible after birth, ideally by breastfeeding and then every 2-3 hours to maintain 
baby’s blood glucose levels. Diabetes is not a contraindication for breastfeeding and women 
should be encouraged to breastfeed. This is a key component the role the specialist midwife 
holds within the MDT by ensuring that women with GDM and T2D have a midwifery 
perspective to their care during pregnancy and postnatally. This enables women to be 
prepared for the postnatal period by giving good advice and helping women to understand 
the importance of breast feeding in reducing the risk of their baby developing diabetes in 
later life. Research in Finland has shown that exclusive breastfeeding for 2–3 months 
significantly reduced the risk of children developing T1D (Virtanen et al, 1991; Virtanen et al, 
1992). Furthermore, the risk of developing T2D in the mother can also be reduced by 
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breastfeeding; researchers in USA found the longer the duration of breastfeeding, the lower 
the incidence of diabetes (Stuebe et al, 2005). Breastfeeding can also contribute to 
postpartum weight loss (Baker et al 2008) which may help in reducing insulin resistance. 
There is no risk of breastfeeding causing hypoglycaemia in T2D unlike T1D (NICE 2008a).  
 
Prior to discharge women should receive appropriate contraceptive advice. CEMACH 
(2007a) found that women with T2D were less likely to receive postnatal contraceptive 
advice than women with T1D. They should also have a postnatal review 6 weeks postpartum 
either at diabetes clinic or with their GP as long as there are no serious obstetric or medical 
complications (Diabetes UK 2008a). Women who had GDM should be advised about their 
increased risk of developing T2D and of increased risk of GDM in subsequent pregnancies 
(NICE 2008a). They should also receive screening for T2D when planning future 
pregnancies and on an annual basis using fasting plasma glucose (NICE 2008a; Diabetes 
UK 2008a). Healthy lifestyle advice focussing on diet, physical activity and optimum BMI 
may help women reduce their risk of T2D in future (NICE 2008a). 
It is possible that some women with GDM may have undiagnosed T2D. Therefore all women 
with GDM should have an OGTT performed 6 weeks postpartum to clarify this. Currently 
NICE (2008a) recommends screening with fasting blood glucose (FBG) only, but an audit in 
Liverpool comparing OGTT to FBG found that 36% of women found to have T2D postnatally 
would have been missed if FBG alone were used (Spelman et al unpublished). Women 
found to have abnormal OGTT postpartum require appropriate referral for T2D management. 
Women with pre-existing T2D require referral back to the appropriate diabetes service for 
routine diabetes care (Diabetes UK 2008a).  
Conclusion 
Gestational and Type 2 diabetes are becoming more prevalent in pregnancy as overweight 
and obesity increases in the general population and T2D is now predominantly more 
common in younger women of child-bearing age. The risks to mother and baby are similar to 
T1D, yet T2D and GDM are often considered less serious conditions often being managed in 
primary rather than specialist maternity care. As a result, women with T2D often receive 
suboptimal preconception care and early antenatal care. Women with T2D and GDM are 
more likely to have additional complications such as obesity, cardiovascular risks, increasing 
age and hypertension, therefore specialist care from all members of the multidisciplinary 
team is essential. Specialist care prior to conception, during pregnancy and in the 
postpartum period not only helps to reduce complications of diabetes in pregnancy but may 
also encourage women to make changes to their diet and lifestyle, improving health in the 
long term. 
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